New Drug from Tonghua Golden-Horse Advances to Final Review Stage, Recent Performance Disclosed

Deep News02-14

According to the latest disclosure by Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. on an investor interaction platform, the company's Class 1 new chemical drug, Succinyl Octahydroaminoacridine Tablets, has completed the comprehensive review process and has entered the final review stage. This development could become a noteworthy event in the near term. The information was officially confirmed by the company on February 12, 2026. Regarding other routine operational matters such as financial reporting, data is based on the third-quarter report of 2025 (revenue of 892 million yuan, net profit attributable to shareholders of 24.9635 million yuan). There is no public information indicating plans for significant shareholder meetings or product launches in the near future. The above content is compiled from publicly available information and does not constitute investment advice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123083908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-14 13:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123083908","market":"sg","top_or_hot":-1,"title":"New Drug from Tonghua Golden-Horse Advances to Final Review Stage, Recent Performance Disclosed","media":"Deep News","content":"<p>According to the latest disclosure by Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. on an investor interaction platform, the company's Class 1 new chemical drug, Succinyl Octahydroaminoacridine Tablets, has completed the comprehensive review process and has entered the final review stage. This development could become a noteworthy event in the near term. The information was officially confirmed by the company on February 12, 2026. Regarding other routine operational matters such as financial reporting, data is based on the third-quarter report of 2025 (revenue of 892 million yuan, net profit attributable to shareholders of 24.9635 million yuan). There is no public information indicating plans for significant shareholder meetings or product launches in the near future. The above content is compiled from publicly available information and does not constitute investment advice.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Drug from Tonghua Golden-Horse Advances to Final Review Stage, Recent Performance Disclosed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Drug from Tonghua Golden-Horse Advances to Final Review Stage, Recent Performance Disclosed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-02-14 13:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest disclosure by Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. on an investor interaction platform, the company's Class 1 new chemical drug, Succinyl Octahydroaminoacridine Tablets, has completed the comprehensive review process and has entered the final review stage. This development could become a noteworthy event in the near term. The information was officially confirmed by the company on February 12, 2026. Regarding other routine operational matters such as financial reporting, data is based on the third-quarter report of 2025 (revenue of 892 million yuan, net profit attributable to shareholders of 24.9635 million yuan). There is no public information indicating plans for significant shareholder meetings or product launches in the near future. The above content is compiled from publicly available information and does not constitute investment advice.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1123083908","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123083908","pubTimestamp":1771047071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"According to the latest disclosure by Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. on an investor interaction platform, the company's Class 1 new chemical drug, Succinyl...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","000766":"通化金马","BK0077":"质押式回购","BK0060":"抗癌"},"translate_title":"通化金马新药挺进终审阶段近期业绩披露","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000766":1},"content_text":"According to the latest disclosure by Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. on an investor interaction platform, the company's Class 1 new chemical drug, Succinyl Octahydroaminoacridine Tablets, has completed the comprehensive review process and has entered the final review stage. This development could become a noteworthy event in the near term. The information was officially confirmed by the company on February 12, 2026. Regarding other routine operational matters such as financial reporting, data is based on the third-quarter report of 2025 (revenue of 892 million yuan, net profit attributable to shareholders of 24.9635 million yuan). There is no public information indicating plans for significant shareholder meetings or product launches in the near future. The above content is compiled from publicly available information and does not constitute investment advice.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123083908","isCrawlerRequest":true}